Advertisement

Increased risk of heart failure and atrial fibrillation in heterozygous familial hypercholesterolemia

      Highlights

      • There is increased risk of coronary artery disease in familial hypercholesterolemia.
      • There is increased risk of heart failure in familial hypercholesterolemia.
      • There is increased risk of atrial fibrillation in familiar hypercholesterolemia.

      Abstract

      Background and aims

      Heart failure (HF) and atrial fibrillation/flutter (AF) are important causes of morbidity and mortality. Subjects with familial hypercholesterolemia (FH) carry a high risk of coronary artery disease (CAD) but it is not known if the risk of HF and AF is increased in FH. The present study investigated the incidence of hospitalization for HF and AF in a genetically verified FH cohort, age 25 years and older, compared to the general population.

      Methods

      Incidence rates of hospitalization for HF and AF were estimated from national registry data. Standardized incidence ratios (SIRs) were calculated.

      Results

      4273 genotyped FH patients (51.7% women) with a total observation period of 18,300 patient years were studied. Overall, the expected number of FH patients with HF was 27.7 and the observed number of cases was 54 (SIR (95% CI) 2.0 (1.5–2.6)). The highest excess risk was observed in the age group 25–49 years, where SIRs were 3.8 (1.2–11.8) and 4.2 (2.0–8.8) in women and men, respectively. The total expected number of FH patients with AF was 39.4 while the observed number of cases was 77 (SIR 2.0 (1.6–2.4)). Among FH patients with an incident event of HF, nearly 90% had a previous diagnosis of CAD, and nearly 40% had suffered from a myocardial infarction.

      Conclusions

      We demonstrate a doubling of the risk of hospitalization for HF or AF in patients with FH. This is could have an important prognostic impact for patients and economic impact for the society.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Heidenreich P.A.
        • Trogdon J.G.
        • Khavjou O.A.
        • Butler J.
        • Dracup K.
        • et al.
        Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.
        Circulation. 2011; 123: 933-944
        • Ponikowski P.
        • Voors A.A.
        • Anker S.D.
        • Bueno H.
        • Cleland J.G.
        • et al.
        2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
        Eur. Heart J. 2016; 37: 2129-2200
        • Verma A.
        • Kalman J.M.
        • Callans D.J.
        Treatment of patients with atrial fibrillation and heart failure with reduced ejection fraction.
        Circulation. 2017; 135: 1547-1563
        • Ference B.A.
        • Ginsberg H.N.
        • Graham I.
        • Ray K.K.
        • Packard C.J.
        • et al.
        Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
        Eur. Heart J. 2017; 38 (e-pub ahead of print 24 April 2017): 2459-2472
        • Krogh H.W.
        • Mundal L.
        • Holven K.B.
        • Retterstøl K.
        Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death.
        Eur. Heart J. 2016; 37: 1398-1405
        • Paquette M.
        • Brisson D.
        • Dufour R.
        • Khoury E.
        • Daniel Gaudet
        • et al.
        Cardiovascular disease in familial hypercholesterolemia: validation and refinement of the Montreal-FH-SCORE.
        J. Clin. Lipidol. 2017; (Epub ahead of print)
        • Mundal L.
        • Veierød M.B.
        • Halvorsen T.
        • Holven K.B.
        • Ose L.
        • et al.
        Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994-2009, a registry study.
        Eur. J. Prev. Cardiol. 2016; 23: 1962-1969
        • Neil A.
        • Cooper J.
        • Betteridge J.
        • Capps N.
        • McDowell I.
        • et al.
        Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
        Eur. Heart J. 2008; 29: 2625-2633
        • Mundal L.
        • Igland J.
        • Ose L.
        • Holven K.B.
        • Veierød M.B.
        • et al.
        Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992-2013.
        Eur. J. Prev. Cardiol. 2017; 24: 137-144
      1. Cardiovascular Disease in Norway 1994-2014. http://cvdnor.b.uib.no (accessed 24 July 2017).

        • Sulo G.
        • Igland J.
        • Nygård O.
        • Vollset S.E.
        • Ebbing M.
        • et al.
        Favourable trends in incidence of AMI in Norway during 2001-2009 do not include younger adults: a CVDNOR project.
        Eur. J. Prev. Cardiol. 2014; 11: 1358-1364
        • Græsdal A.
        • Bogsrud M.P.
        • Holven K.B.
        • NenseterI M.S.
        • Narverud I.
        • et al.
        Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia.
        J. Clin. Lipidol. 2012; 6: 331-339
        • Leren T.P.
        • Berge K.E.
        Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated.
        PLoS One. 2011; 6: e16721
        • Toleikyte I.
        • Retterstøl K.
        • Leren T.P.
        • Iversen P.O.
        Pregnancy outcomes in familial hypercholesterolemia: a registry-based study.
        Circulation. 2011; 124: 1606-1614
        • Mundal L.
        • Sarancic M.
        • Ose L.
        • Iversen P.O.
        • Borgan J.K.
        • et al.
        Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010.
        J. Am. Heart Assoc. 2014; 3: e001236
        • Pedersen A.G.
        • Ellingsen C.L.
        Data quality in the causes of death registry.
        Tidsskrift den Norske laegeforening. 2015; 135: 768
        • Rothman K.J.
        Modern Epidemiology.
        third ed. 2015
        • Slack J.
        Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.
        Lancet. 1969; 2: 1380-1382
        • Nanchen D.
        • Gencer B.
        • Muller O.
        • Auer R.
        • Aghlmandi S.
        • et al.
        Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes.
        Circulation. 2016; 134: 698-709
        • Chioncel O.
        • Lainscak M.
        • Seferovic P.M.
        • Anker S.D.
        • Crespo-Leiro M.G.
        • et al.
        Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
        Eur. J. Heart Fail. 2017; (E-pub)
        • Staerk L.
        • Sherer J.A.
        • Ko D.
        • Benjamin E.J.
        • Helm R.H.
        Atrial fibrillation epidemiology, pathophysiology, and clinical outcomes.
        Circ. Res. 2017; 120: 1501-1517
        • Lozano P.
        • Henrikson N.B.
        • Dunn J.
        • Morrison C.C.
        • Nguyen M.
        • et al.
        Lipid screening in childhood and adolescence for detection of familial hypercholesterolemia: evidence report and systematic review for the US preventive services task force.
        JAMA. 2016; 316: 645-655
        • Heidenreich P.A.
        • Albert N.M.
        • Allen L.A.
        • Bluemke D.A.
        • Butler J.
        • et al.
        Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.
        Circ. Heart Fail. 2013; 6: 606-619
        • Kim M.H.
        • Johnston S.S.
        • Chu B.C.
        • Dalal M.R.
        • Schulman K.L.
        Estimation of total incremental health care costs in patients with atrial fibrillation in the United States.
        Circ. Cardiovasc Qual. Outcomes. 2011; 4: 313-320
        • Limone B.L.
        • Baker W.L.
        • Kluger J.
        • Coleman C.I.
        Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models.
        PLoS One. 2013; 8: e62183
        • Wiegman A.
        • Gidding S.S.
        • Watts G.F.
        • Chapman M.J.
        • Ginsberg H.N.
        • et al.
        Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.
        Eur. Heart J. 2015; 36: 2425-2437
        • Nordestgaard B.G.
        • Benn M.
        Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world?.
        Eur. Heart J. 2017; 38: 1580-1583
        • Barasa A.
        • Schaufelberger M.
        • Lappas G.
        • Swedberg K.
        • Dellborg M.
        • et al.
        Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden.
        Eur. Heart J. 2013; 35: 25-32
        • Schocken D.D.
        • Benjamin E.J.
        • Fonarow G.C.
        • Krumholz H.M.
        • Levy D.
        • et al.
        Prevention of heart failure: a scientific statement from the American heart association councils on epidemiology and prevention, clinical cardiology, cardiovascular nursing, and high blood pressure research; quality of care and outcomes research interdisciplinary working group; and functional genomics and translational biology interdisciplinary working group.
        Circulation. 2008; 117: 2544-2565
        • Shin J.J.
        • Hamad E.
        • Murthy S.
        • Piña I.L.
        Heart failure in women.
        Clin. Cardiol. 2012; 35: 172-177